In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen-discovered immune checkpoint regulators. Under the terms of the agreement, Bayer and Compugen have jointly pursued a preclinical research program. Bayer has taken full control over further development and have worldwide commercialization rights for potential cancer therapeutics for one of the programs, CGEN- 15001T, for which preclinical stage milestones have been achieved and preclinical development is on track.
“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups at Bayer HealthCare